Go Pro

Douglas Miehm Analyst Performance

Analyst at Royal Bank Of Canada

Douglas Miehm is a stock analyst at Royal Bank Of Canada in the healthcare sector, covering 9 publicly traded companies. Over the past year, Douglas Miehm has issued 17 stock ratings, including buy and hold recommendations. While full access to Douglas Miehm's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Douglas Miehm's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
75 Last 11 Years
Buy Recommendations
48.65% 36 Buy Ratings
Companies Covered
9 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy48.6%36 ratings
Hold51.4%38 ratings
Sell0.0%0 ratings

Out of 74 total stock ratings issued by Douglas Miehm at Royal Bank Of Canada, the majority (51.4%) have been Hold recommendations, followed by 48.6% Buy.

Exchange Coverage

ExchangePercentageCount
NASDAQ
55.6% of companies on NASDAQ
5 companies
NYSE
22.2% of companies on NYSE
2 companies
TSE
11.1% of companies on TSE
1 company
OTCMKTS
11.1% of companies on OTCMKTS
1 company

Douglas Miehm, an analyst at Royal Bank Of Canada, currently covers 9 companies listed on NASDAQ, NYSE, TSE and OTCMKTS, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Healthcare
9 companies
100.0%

Douglas Miehm of Royal Bank Of Canada specializes in stock coverage within the Healthcare sector.

Coverage Industries

IndustryPercentage
BIOTECHNOLOGY
4 companies
44.4%
PHARMACEUTICALS
3 companies
33.3%
HEALTHCARE EQUIPMENT & SUPPLIES
2 companies
22.2%

Douglas Miehm's Ratings History at Royal Bank Of Canada

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
8/7/2026Boost Price Target$15.99$16.00Sector Perform
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
8/7/2026Boost Price Target$291.09$345.00Outperform
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
8/5/2026Boost Price Target$24.19$25.00Sector Perform
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
7/15/2026Boost Price Target$298.98$340.00Outperform
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
5/8/2026Boost Price Target$219.55$262.00Outperform
MannKind Corporation stock logo
MNKD
MannKind
5/7/2026Boost Price Target$3.61$4.75Sector Perform
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
5/1/2026Boost Price Target$24.15$24.00Sector Perform
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
4/28/2026Boost Price Target$238.78$252.00Outperform
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
4/27/2026Lower Price Target$5.71$9.00Sector Perform
MannKind Corporation stock logo
MNKD
MannKind
2/27/2026Reiterated Rating$3.24$3.50Sector Perform
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
1/27/2026Boost Price Target$16.91$21.00Outperform
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
12/10/2025Boost Price Target$187.43$235.00Outperform
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
11/14/2025Boost Price Target$15.47$19.00Outperform
MannKind Corporation stock logo
MNKD
MannKind
11/11/2025Lower Price Target$5.27$7.50Outperform
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
11/10/2025Boost Price Target$201.57$234.00Outperform
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
11/5/2025Reiterated Rating$14.27$15.00Sector Perform
MannKind Corporation stock logo
MNKD
MannKind
8/26/2025Boost Price Target$3.95$8.00Outperform
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
8/8/2025Boost Price Target$150.84$185.00Outperform
MannKind Corporation stock logo
MNKD
MannKind
8/7/2025Lower Price Target$3.42$7.00Outperform
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
8/1/2025Boost Price Target$10.01$9.00Outperform
MannKind Corporation stock logo
MNKD
MannKind
7/23/2025Lower Price Target$3.93$8.00Outperform
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
5/2/2025Boost Price Target$5.45$10.00Sector Perform
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
4/4/2025Lower Price Target$12.32$17.00Outperform
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
3/10/2025Lower Price Target$0.66$5.00Outperform
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
2/20/2025Lower Price Target$16.11$18.00Outperform
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
1/30/2025Lower Price Target$7.41$10.00Sector Perform
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
1/29/2025Lower Price Target$17.79$22.00Outperform